Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
| Overview / Abstract: |
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-selectin, and SMO. Dr. Jonas utilizes case studies to share his insights in the treatment of patients with AML. |
|
Expiration |
Sep 30, 2024 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
0.75 |
|
Accreditation |
ACCME, ANCC |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Brian Jonas, MD, PhD |
|
Sponsors / Supporters / Grant Providers |
This educational activity is supported by an educational grant from AbbVie. |
|
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Acute Myeloid Leukemia, AML Free CE CME Live CE CME |
|